logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-9. Secondary drug used: percentage among all cannabis (primary drug) clients attending outpatient treatment in 2002

Country Opiates Cocaine Stimulants Hypnotics/ sedatives Hallucin ogens Volatile inhalants Alcohol Other substances Base N.
                   
Czech Republic 9.2 0.2 48.4 1.7 19.3 6.6 13.1 1.5 980  
Germany 7.1 13.3 37.7 2.7 13.4 0.5 23.9 1.3 5887  
Denmark 13.8 14.8 30 7.8 2.8 0.6 26.6 3.7 656  
Greece 21 13.3 18.9 18.9 10.5 6.3 6.3 4.9 148  
Spain 3.4 30.9 13.5 2.6 3.5 0.4 43.3 2.5 3241  
Latvia 26 0 21.7 30.4 8.7 4.4 4.4 4.4 23  
Luxembourg 51.8 12.5 5.4 8.9 1.8 1.8 17.9 0 56  
Hungary 3.5 0 4 0.5 0.5 6.5 78.1 7 201  
Netherlands 3.9 25.3 17.1 2.7 0.8 0 47.3 2.7 659  
Slovenia 26.6 3.1 15.6 4.7 3.1 1.6 45.3 0 64  
Finland 5.3 0 33.8 9.8 0.2 0.4 50 0.4 450  
Sweden 8.6 4.7 41.4 17.7 4.3 0.4 22.8 0 232  
                     
Notes:                    
The percentages are based on the total number of outpatient treatment cases with cannabis as a primary drug.    
                     
Source: 2003 Reitox national reports, TDI - outpatient treatment centres.    
                     

Download
Download this attachment in XLS format